Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail

作     者：Jyoti Bajpai Surya Kant Ajay Kumar Verma Akshyaya Pradhan 

作者机构：Department ofRespiratory MedicineKing George’s Medical UniversityLucknow 226003India Department ofCardiologyKing George’s Medical UniversityLucknow 226003India 

出 版 物：《World Journal of Respirology》 (世界呼吸病学杂志)

年 卷 期：2023年第12卷第1期

页      面：1-9页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：SARS-CoV-2 Mild COVID-19 Antibodies Risk factors 

摘      要：The coronavirus disease 2019(COVID-19)pandemic has had a tremendous adverse impact on the global health system,public sector,and social *** is unarguably the worst pandemic of the ***,COVID-19 management is a mystery in front of us,and an authentic treatment is urgently *** repurposed drugs,like ivermectin,remdesivir,tocilizumab,baricitinib,etc.,have been used to treat COVID-19,but none are *** therapy and their combinations are emerging modalities for treating moderate COVID-19,and they have shown the potential to reduce *** antibody monotherapy,bamlanivimab,and two cocktails,casirivimab/imdevimab and bamlanivimab/esterivimab,have received authorization for emergency use by the United States Food and Drug Administration for the treatment of mild COVID-19 in high risk *** European Emergency has made similar recommendations for use of the drug in COVID-19 patients without oxygen *** brief review will focus on monoclonal antibodies and their combination cocktail therapy in managing COVID-19 infection.